. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: J Cardiopulm Rehabil Prev. 2019 May;39(3):199–203. doi: 10.1097/HCR.0000000000000388

Table 2.

Repeated measures ANOVA for intervention group^†, time, and interaction effects

	Group (n)	Baseline	Follow-Up	Group P Value	Time P Value	Group by Time P-Value
Cardiac Health
VO_2max (mL/kg/min)	Control (7)	14.8 (2.0) 9.4–23.2	14.1 (2.0) 8.4–22.8	0.62	0.98	0.042^*
	Intervention (8)	13.5 (1.9) 6.9–17.5	14.3 (2.0) 8.4–29.5
LVEF (%)	Control (6)	53.3 (3.6) 42.0–62.0	52.8 (3.0) 40.0–62.0	0.17	0.62	0.46
	Intervention (7)	45.0 (3.6) 32.0–58.0	48.0 (3.0) 40.0–58.0
MDASI-HF
Symptom severity	Control (6)	30.7 (3.5) 14.0–41.0	33.3 (2.8) 27.0–39.0	0.41	0.18	0.97
	Intervention (10)	27.2 (2.7) 18.0–40.0	30.2 (2.2) 16.0–45.0
Symptom burden	Control (6)	13.3 (1.9) 4.0–18.0	13.8 (1.4) 11.0–16.0	0.87	0.66	0.91
	Intervention (10)	13.1 (1.5) 7.0–18.0	13.4 (1.1) 7.00–18.0
Cardiac health	Control (6)	5.00 (1.5) 0.0–12.0	2.83 (1.4) 0.00–6.00	0.22	0.30	0.053
	Intervention (10)	1.40 (1.1) 0.0–4.00	2.10 (1.01) 0.00–11.0
SF-36
Physical functioning	Control (8)	37.0 (8.5) 10.0–65.0	53.8 (9.8) 25.0–100	0.17	0.001^*	0.15
	Intervention (10)	58.5 (7.6) 20.0–100	66.5 (8.8) 30.0–95.0
Role functioning	Control (8)	35.9 (8.4) 0.00–68.0	49.2 (10.7) 12.5–100	0.09	0.03^*	0.99
	Intervention (10)	57.5 (7.5) 12.5–100	70.6 (9.6) 12.5–100
CHAMPS
Total hours	Control (8)	13.7 (3.3) 2.2–35.3	11.4 (2.3) 2.80–21.5	0.25	0.82	0.40
	Intervention (10)	8.03 (3.0) 0.5–21.0	9.38 (2.1) 3.00–21.3
High intensity hours	Control (8)	4.25 (1.6) 0.0–9.75	4.72 (1.8) 0.00–14.0	0.92	0.60	0.83
	Intervention (10)	3.75 (1.5) 0.0–15.5	4.85 (1.6) 0.00–14.5

P < .05

^†

For purposes of analysis, the clinic-based exercise condition was combined with the home-based exercise condition to form a single intervention comparison group.

Data are presented as mean ± SE, range